Why the study?
Type 2 diabetes mellitus is associated with vascular complications linked to dysregulated platelet reactivity, prompting investigation into the relationship between mean platelet volume and glycaemic control in new-onset disease.
Does improvement in glycaemic control reduce mean platelet volume in patients with new-onset Type 2 diabetes mellitus?
Does improvement in glycaemic control reduce mean platelet volume in patients with new-onset Type 2 diabetes mellitus?
In patients with new-onset T2DM and baseline HbA1c ≥ 8%, improvement in glycaemic control is associated with a significant decrease in mean platelet volume, suggesting MPV could be a marker for glycaemic control.
MPV may track glycaemic control in new-onset T2DM; hypothesis-generating for biomarker use and should not yet change practice.
Introduction: Type 2 diabetes mellitus (T2DM) is a metabolic disorder associated with vascular complications that are attributable to dysregulated platelet reactivity as measured by mean platelet volume (MPV). This study aimed at determining a relationship between MPV and glycaemic control in new-onset T2DM. Methods: This was a prospective study conducted on 236 new-onset T2DM patients divided in two groups as group A, glycosylated haemoglobin A1c (HbA1c < 7.9%; n = 70) and group B, HbA1c ⩾ 8% ( n = 107) who were followed up for 6 months for change in platelet and glycaemic parameters. Results: At 6-month follow-up, there was a significant decrease in HbA1c and MPV (group A (HbA1c: 7.40 ± 0.40 vs 7.03 ± 0.23%, p < 0.03; MPV: 9.65 fl ± 0.74 vs 9.46 fl ± 0.71, p < 0.001) and group B (HbA1c: 10.59 ± 1.89% vs 9.29 ± 1.50%, p < 0.001; MPV: 10.89 fL ± 1.29 vs. 10.23 fL ± 1.40, p< 0.001)). The percentage decline in HbA1c was more in group B (11.81 ± 5.87 vs 4.76 ± 4.58, p < 0.01). There was a positive correlation between ΔMPV and ΔHbA1c in group B; however, we did not observe significant correlation for group A. Conclusion: We interpret that in people with diabetes with baseline HbA1c ⩾ 8%, with improvement in glycaemic control, there is a significant decrease in MPV. We propose that a routine MPV testing can be used as a potential marker for glycaemic control in T2DM.
No takes yet. Share an insight, caveat, or question.
Gulia et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: